---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-033314"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:27:36.006956+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BeiGene option for DKN-01 expired; Leap retains global rights, continues clinical collaboration

## Summary
- BeiGene's option to license DKN-01 in Asian territories expired; Leap retains global rights.
- Collaboration continues on Part C of DisTinGuish trial (DKN-01 + tislelizumab + chemo) in first-line gastric cancer; enrollment completion expected late 2023.
- Cash runway extended into mid-2025 following Flame Biosciences acquisition; company seeking new strategic partner for DKN-01.
- Company will also develop Claudin18.2 programs acquired from Flame as part of focus on GI cancers.

## SEC filing metadata
- accession: 0001104659-23-033314
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.03, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465923033314/0001104659-23-033314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465923033314/tm239782d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-033314
- JSON: https://secwatch.observer/filing/0001104659-23-033314.json
- Plain text: https://secwatch.observer/filing/0001104659-23-033314.txt

## Key facts
- Governance Changes
  CYPHERPUNK TECHNOLOGIES INC.: Increased ownership threshold required for special voting stock holder to designate a director from 5% to 9.9% (effective 2023-03-16).
  - Change: charter amendment
  - Effective: 2023-03-16
  source text: to provide for an increase in the percentage of outstanding shares of Common Stock of the Company that the sole holder of the Company’s Special Voting Stock, together with its affiliates and associates, must hold from 5% to 9.9% in order for such sole holder of the Company’s Special Voting Stock to have the right to designate one (1) individual as a director on the Board of Directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465923033314/0001104659-23-033314-index.htm
- Material Agreements
  CYPHERPUNK TECHNOLOGIES INC. entered into Letter Agreement with BeiGene, Ltd. (effective 2023-03-16).
  - Action: entry
  - Counterparty: BeiGene, Ltd.
  - Effective: 2023-03-16
  source text: On March 16, 2023, Leap Therapeutics, Inc. (the “Company”) and BeiGene, Ltd. (“BeiGene”) entered into a letter agreement (the “Letter Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465923033314/0001104659-23-033314-index.htm
- Shareholder Votes
  CYPHERPUNK TECHNOLOGIES INC. shareholders approved Approval of Amendment to the Certificate of Designation of the Company's Special Voting Stock at the 2023-03-16 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-03-16
  source text: To consider and vote upon a proposal to amend the Certificate of Designation of Special Voting Stock of the Company as set forth in the Certificate of Amendment. 1 0 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465923033314/0001104659-23-033314-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.